Advertisement

Is Renal Cancer a Hormone-Dependent Tumour and How Does it Respond to Hormonal Treatment? Round Table Report

  • J. Altwein
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

Despite the lack of clinical data to support the concept of renal cell carcinoma (RCC) as a “hormone dependent tumour” — the title of a paper from Concolino in Cancer Research in 1978 (1) — hormone therapy is still being used in many institutions.

Keywords

Renal Cell Carcinoma Renal Cell Carcinoma Cell Renal Carcinoma Renal Cell Carcinoma Patient Medroxyprogesterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. Concolino, A. Marrachi, C. Conti, R. Tenaglia, F. Di Silverio and U. Bracci, Human Renal Cell Carcinoma as a Hormone-Dependent Tumor, Cancer Res, 38:4340 (1978).PubMedGoogle Scholar
  2. 2.
    M. Marberger Jr., J.E. Altwein and F. Orestano, The Influence of the Progestagen Gestonorone Caproate on Testosterone Turnover in Renal Cell Carcinoma, Invest. Urol. 13:302 (1976).PubMedGoogle Scholar
  3. 3.
    U. Dunzendorfer, D. Drahovsky, H. Schmidt-Gayk and H.P. Zahradnik, Klinische Bedeutung der Peptilhormone LH, FSH, TSH, Prolaktin, HCG, Parathormon, Calcitonin, Prostaglandin F2 beim Nierenkarzinom, Z. Urol. Nephrol. 74:13 (1981).PubMedGoogle Scholar
  4. 4.
    B. van der Werf-Messing, Prognostic Factors in Renal Cancer, in “Cancer of the Prostate and Kidney”, P.H. Smith and M. Pavone-Macaluso (eds), Plenum Publishing Company Ltd., London and New York (1982).Google Scholar
  5. 5.
    R.E. Bellett and A.P. Squitieri, Estrogen-Induced Hypernephroma, J. Urol. 112:60 (1974).Google Scholar
  6. 6.
    I. Nissenkorn, C. Servadio and I. Avidor, Oestrogen-Induced Renal Cell Carcinoma, Brit. J. Urol. 51:6 (1979).PubMedCrossRefGoogle Scholar
  7. 7.
    H. Bojar, K. Marz and W. Staib, The Endocrine Background of Renal Cell Carcinoma I, Urol. Int. 34:302 (1979).PubMedCrossRefGoogle Scholar
  8. 8.
    J.J. Li, S.A. Li and J.L. Cuthbertson, Nuclear Retention of All Steroid Hormone Receptor Classes in the Hamster Renal Carcinoma, Cancer Res. 39:2647 (1979).PubMedGoogle Scholar
  9. 9.
    W.J. Hrushesky and G.P. Murphy, Current Status of the Therapy of Advanced Renal Carcinoma, J. Surg. Oncol. 9:277 (1977).PubMedCrossRefGoogle Scholar
  10. 10.
    J.B. DeKernion and D. Berry, The Diagnosis and Treatment of Renal Cell Carcinoma, Cancer 45:1947 (1980).PubMedGoogle Scholar
  11. 11.
    S.S. Legha, N. Slavik and S.K. Carter, Nafoxidine — An Anti-estrogen for the Treatment of Breast Cancer, Cancer 38:1535 (1976).PubMedCrossRefGoogle Scholar
  12. 12.
    D.R. Ishmael, L.J. Burpo and R.H. Bottomley, Combined Therapy of Advanced Hypernephroma with Medroxyprogesterone, BCG, Adriamycin and Vincristine, Proc. Am. Assoc. Cancer Res. Am Soc. Clin. Oncol. 19:407 (1978).Google Scholar
  13. 13.
    S. Brosman, Immunotherapy for Renal Carcinoma, in “Cancer of the Prostate and Kidney”, P.H. Smith and M. Pavone-Macaluso (eds) Plenum Publishing Company Ltd., London and New York (1982).Google Scholar
  14. 14.
    G.P. Bodey, Current Status of Chemotherapy in Metastatic Renal Carcinoma, in “Cancer of the Genitourinary Tract, D.E. Johnson M.L. Samuels (eds), Raven Press, New York (1979) p. 67.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. Altwein
    • 1
  1. 1.Bundeswehrkrankenhaus UlmUlmWest Germany

Personalised recommendations